A P. Hospers

Groningen, GR, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Metastatic mismatch repair deficient oesophageal squamous cell carcinoma leading to diagnosis of Lynch syndrome with a complete response to nivolumab treatment.

Metastatic mismatch repair deficient oesophageal squamous cell carcinoma leading to diagnosis of Lynch syndrome with a complete response to nivolumab treatment.

Journal: Virchows Archiv : an international journal of pathology

Published: August 04, 2025

Induction therapy with BRAF/MEK inhibitors versus upfront ipilimumab/nivolumab in poor prognostic advanced melanoma.

Induction therapy with BRAF/MEK inhibitors versus upfront ipilimumab/nivolumab in poor prognostic advanced melanoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 10, 2025

Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry.

Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 28, 2025

Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 25, 2025

Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.

Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.

Journal: British journal of cancer

Published: January 13, 2025

Corrigendum to "Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry" [Eur. J. Cancer 212, 2024, 115056].

Corrigendum to "Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry" [Eur. J. Cancer 212, 2024, 115056].

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 28, 2024

Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy.

Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy.

Journal: British journal of cancer

Published: October 04, 2024

Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma.

Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma.

Journal: Immuno-oncology technology

Published: July 24, 2024

Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry.

Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 21, 2024

Corrigendum to "Authors' reply-Does the RAPIDO trial suggest a benefit of post-operative chemotherapy after preoperative chemoradiation in rectal cancer? No, it does not": [ESMO Open 8 (2023) 101645].

Corrigendum to "Authors' reply-Does the RAPIDO trial suggest a benefit of post-operative chemotherapy after preoperative chemoradiation in rectal cancer? No, it does not": [ESMO Open 8 (2023) 101645].

Journal: ESMO open

Published: October 22, 2023

ASO Author Reflections: A Systematic Review on Predictive Immune and Metabolic Biomarkers to Predict Clinical and Pathological Response in Esophageal Cancer.

ASO Author Reflections: A Systematic Review on Predictive Immune and Metabolic Biomarkers to Predict Clinical and Pathological Response in Esophageal Cancer.

Journal: Annals of surgical oncology

Published: October 06, 2023

Authors' reply-Does the RAPIDO trial suggest a benefit of post-operative chemotherapy after preoperative chemoradiation in rectal cancer? No, it does not.

Authors' reply-Does the RAPIDO trial suggest a benefit of post-operative chemotherapy after preoperative chemoradiation in rectal cancer? No, it does not.

Journal: ESMO open

Published: August 10, 2023

Showing 1-12 of 31

Last Updated: 09/26/2026